৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Quantity:
Products
Payment
Delivery
Indications
Adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus.
Limitations of use:
Not studied in patients with a history of pancreatitis.
Not indicated for type 1 diabetes mellitus.
Pharmacology Tirzepatide is a dual GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that binds albumin, prolonging half-life. It enhances insulin secretion (first and second phase) and reduces glucagon levels in a glucose-dependent manner.
Dosage & Administration
Route: Subcutaneous injection.
Starting dose: 2.5 mg once weekly (initiation only, not for glycemic control).
Titration: Increase to 5 mg after 4 weeks; further increments of 2.5 mg every ≥4 weeks if needed.
Maximum dose: 15 mg once weekly.
Missed dose: Administer within 4 days; if >4 days, skip and continue regular schedule.
Administration: Inject in abdomen, thigh, or upper arm. Rotate sites. Do not mix with insulin, though both may be injected in the same region separately.
Handling: Do not freeze. Protect from light. Inspect syringes for particulate matter/discoloration.
Interactions
Reduce dose of insulin or sulfonylureas to lower hypoglycemia risk.
Delays gastric emptying → may affect absorption of oral drugs (e.g., warfarin).
Oral contraceptives: switch to non-oral or add barrier method for 4 weeks after initiation or dose escalation.
Contraindications
Hypersensitivity to tirzepatide or components.
Personal/family history of medullary thyroid carcinoma (MTC).
Patients with MEN 2.
Side Effects
Common: Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain.
Pregnancy & Lactation
Use only if benefits outweigh risks. Poorly controlled diabetes poses risks to mother and fetus.
Breastfeeding: weigh maternal need against potential infant exposure.
Precautions & Warnings
Counsel on thyroid tumor risk (MTC).
Monitor for pancreatitis; discontinue if suspected.
Adjust concomitant insulin/secretagogues to reduce hypoglycemia risk.
Monitor renal function in impaired patients.
Monitor progression of diabetic retinopathy.
Evaluate gallbladder if cholelithiasis suspected.
Special Populations
Not established in patients <18 years.


Tirzepatide is an injectable medication used for type 2 diabetes management and, in many cases, weight management. It works as a dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar and appetite.
Tirzepatide helps lower blood glucose levels, improve insulin sensitivity, reduce appetite, and support significant weight loss. It may also reduce cardiovascular risk factors in patients with type 2 diabetes.





